Just a moment, the page is loading...

GSK-204716




A 24-week, Phase III, open-label, non-comparative, multi-center study to evaluate efficacy and safety of GSK1278863 in Japanese hemodialysis subjects with anemia associated with chronic kidney disease who are not taking erythropoiesis stimulating agents
daprodustat
204716
NCT02829320
Anaemia
Phase 3
This study is available in CDISC format.
September 2019